Oncolys BioPharma Inc.
 
"The 5th Japan
Bio-Venture Award"
Award by Minister of Education, Culture, Sports, Science and Technology.
Oncolys is seeking partnering opportunities for our lead compounds. For more information visit our Partnering opportunities page on this site or contact us at anticancer@oncolys.com
Oncolys BioPharma is a privately held biopharmaceutical company focused on the development of novel biologics for the treatment of cancer and infectious disease.

We believe that through the development of replication-competent oncolytic virus and micrometastatic tumor diagnostic viruses, we produce safer, more effective, QOL-improving approaches aiming to revolutionize the current mode of cancer therapy.

Our lead compound for the treatment of cancer, Telomelysin® (OBP-301), is in Phase-I clinical development in the US and is being tested in clinical trials for various solid tumors.

Our novel cancer diagnostic compound, Telomescan® (OBP-401), is in a validation stage (feasibility studies) and is expected to effective in detecting most types of cancer.

Our lead compound for infectious disease, FESTINAVIR®(OBP-601), is in Phase-I for HIV/AIDS therapy. OBP-601 is a novel NRTI with highly promising safety and resistance profiles.
| HOME |
Copyright (c)2004-2005, Oncolys BioPharma Inc. All rights reserved.